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Chapter-III





Synopsis




The work carried out during my research tenure has been compiled in the form of a thesis entitled "Combinatorial Synthesis of Pyrrolobenzodiazepine Antibiotics". The main aim of this work is to generate libraries of large number of biologically active molecules like pyrrolobenozodiazepines, which are known to be DNA-binding and potentially anticancer molecules. Efforts have been made to find out their activity against bacteria like mycobacterium tuberculosis. The thesis has been divided into four chapters.
Chapter I: This chapter covers the general introduction about drug discovery, combinatorial chemistry, pyrrolobenzodiazepines, the aim and objectives of the present work. 
Chapter II: This chapter deals with the generation of 210 compound library of pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones on solid-phase and their screening against Mycobacterium tuberculosis, which is the causes tuberculosis.
Chapter III: This chapter describes the development of solid-phase synthetic strategies for pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotics and this chapter has been divided in to three sections. Section A: This section consists of the reduction of aromatic nitro/azido functionality on solid-support employing Al/NiCl2.6H2O and Al/NH4Cl and these reagents have been utilized for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines on solid-support. 
Section B: This section deals with a new traceless approach for the solid-phase synthesis of pyrrolo[2,1-c][1,4]benzodiazepines involving intramolecular aza-Wittig cyclization through reductive cleavage by employing DIBAL-H. 
Section C: This section comprises of the solid phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines by using chloromethyl Wang resin attached to isatoic anhydride as the starting material and synthetic route involving cyclocondensation followed by reductive cleavage. 
Chapter IV: This chapter comprises of polymer-assisted solution phase strategy for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepine anticancer agents, including naturally occurring DC-81 antibiotic.

Chapter I
Introduction

In this chapter deals with the general introduction about Drug Discovery, Combinatorial Chemistry and Pyrrolobenzodiazepines. Since the beginning of modern synthetic organic chemistry, the goal of chemists has been to produce single compounds in as pure a form as possible. In this way many new organic molecules were prepared as drug candidates and submitted to biological tests. Generally, thousands of new materials had to be prepared to find a single new drug entity. The one-by-one synthesis of thousands of new compounds followed by their one-by-one testing made the drug discovery process a very tedious, time consuming and expensive task. Finding of novel drug is a complex process. Historically, the main source of biologically active compounds used in drug discovery programs has been natural products, isolated from plant, animal or fermentation sources.

Combinatorial Chemistry

Combinatorial chemistry is a new methodology developed by researchers in the pharmaceutical industry to reduce the time and costs associated with producing effective and competitive new drugs. By accelerating the process of chemical synthesis, this method is having a profound effect on all branches of chemistry, especially on drug discovery. Through the rapidly evolving technology of combinatorial chemistry, it is now possible to produce libraries of small molecules to screen for novel bioactivities. This powerful new technology has begun to help pharmaceutical companies to find new drug candidates quickly, save significant money in preclinical development costs and ultimately change their fundamental approach to drug discovery. 
Combinatorial chemistry is used to synthesize large number of chemical compounds by combining sets of building blocks. Each newly synthesized compound’s composition is slightly different from the previous one. In this way the bench chemists can single handedly prepare many hundreds or thousands of compounds in the time usually taken to prepare only a few by orthodox methodologies. Over the last few years, the combinatorial chemistry has emerged as an exciting new paradigm for the drug discovery. In a very short time the topic has become the focus of considerable scientific interests and research efforts.

Pyrrolo[2,1-c][1,4]benzodiazepine Antibiotics

Cancer is a diseases characterized by uncontrolled growth or spread of abnormal cells. Since it involves the conversion of any normal cells to a cancerous cell showing tandem replication and cell division at much faster rate in comparison to the normal cells and thus provides a potential target area for the development of chemotherapeutic agents. It is now clear that chemotherapy’s most effective role in solid tumours is as an adjuvant to initial therapy by surgical or radiotherapeutic procedures. Chemotherapy becomes critical to effective treatment because only systemic therapy can attack micrometastases. These agents can be categorized into functional subgroups like alkylating agents, antimetabolites, antibiotics, and antimitotics. The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) belonging to the class of DNA-interactive antitumour antibiotics have the potential as regulators of gene expression with possible therapeutic application in the treatment of genetic disorders including cancer. The first PBD antitumour antibiotic anthramycin has been described by Leimgruber et. al. in 1963, and since then a number of compounds have been developed on PBD ring system leading to DNA binding ligands. 



Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of potent naturally occurring low molecular weight antitumour antibiotics originally isolated from various Streptomyces species. Their common interaction with DNA has been extensively investigated and it is considered unique since they bind within the minor groove of DNA forming a covalent aminal bond between the C11-position of the central B-ring and the N2 amino group of guanine base. A number of naturally occurring and synthetic compounds based on PBD ring system, such as anthramycin, tomaymycin, DC-81 and its dimmers (presently, SJG-136 is under clinical evaluation), have shown varying degrees of DNA binding affinity and anti-cancer activity. 

Chapter II
Solid-Phase Synthesis of a Library of Pyrrolobenzodiazepine-5,11-diones with Potential Antitubercular Activity

The benzodiazepine moiety has gained much attention in the synthetic community, mainly because for its representation as a member of the family of ‘privileged scaffolds’. In fact, the first heterocyclic templates prepared on a solid-support has been that of 1,4-benzodiazepines followed by a large number of reports on the synthesis of similar skeleton. Pyrrolo[2,1-c][1,4]benozodiazepine-5,11-dione is merely the proline fused 1,4-benzodiazepine-2,5-dione scaffold. However, not much efforts have been made for the development of solid-phase synthesis of such pyrrolo[2,1-c][1,4]benozodiazepine-5,11-diones. This tricyclic ring system has been used for a number of pharmaceutical applications, such as template for design and assembly of peptidomimetic agents, anxiolytic drugs, anticonvulsants and herbicides. Interestingly, N(10)-substituted pyrrolo[2,1-c][1,4]benozodiazepine-5,11-diones have shown enhanced biological activity compared to the corresponding hydrogen analogues particularly in the preclinical study of anxiolytic agents
A versatile combinatorial approach has been developed and utilized for the rapid synthesis of pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dione (PBD-5,11-dione) libraries 10, 15 and 19 containing 210 compounds with varied substitutions in A, B and C rings. The key aspect of the synthetic strategy includes Staudinger, intermolecular aza-Wittig reaction followed by imine reduction and base mediated cyclative cleavage results in the formation of final resin free compounds. The synthetic design includes, the preparation of a large array of resin bound 2-azidobenzoyl proline acids, the generation of iminophosphoranes from these corresponding proline acids, and the solid-phase aza-Wittig reaction of the iminophosphorane intermediates to imino derivatives followed by their reduction to the corresponding amino compounds, which, undergo intramolecular cyclization by the cleavage of the resin. Moreover, the N-alkylation and esterification at C2 position has been achieved by employing this synthetic sequence.
The Merrifield resin (1) is coupled to the Boc protected L-proline (2) in presence of potassium fluoride to give the corresponding resin-bound proline acid (3). The Boc group of 3 was deprotected upon treatment with trifluoroacetic acid (TFA/CH2Cl2, 3:7) followed by its washing with triethylamine (1% Et3N/THF) to give the resin-bound proline. The Boc-deprotected resin bound proline acid (4) is coupled with different 2-azidobenzoic acids (5{1-11}), employing EDCI and HOBt to afford the desired resins (6). (Scheme 1). 



The compounds 6 thus obtained are treated with a five fold excess triphenylphosphine in dry toluene at room temperature to produce the iminophosphorane intermediate resins (6a) and condensed with different aldehydes (7) to yield the corresponding imines (8). This step is repeated in CH2Cl2 under reflux condition to ensure that the entire iminophosphorane intermediate was converted to the imino compound. These imines (8) are later reduced with NaCNBH3 in 1% AcOH-DMA to give the amino substituted products (9), and this step is once again repeated for complete reduction. Resin bound amino compounds (9) are finally cyclized by treating with lithiated 5-phenyl-2-oxazolidinone to afford the desired PBD-5,11-diones 10 as illustrated in Scheme 2. 
Additionally, the hydroxyl group of resin-bound N-(2-azidobenzoyl)-4-hydroxypyrrolidine-2-carboxylic acids 6 is activated to obtain different types of esters 12 by treatment with respective chlorides 11. These compounds (12) are treated with a five fold excess of triphenylphosphine in dry toluene at room temperature to produce the iminophosphoranes (12a) and this upon condensation with different aldehydes (7) provide the corresponding imines (13). The imines are reduced with NaCNBH3 in 1% AcOH-DMA to give the amino resins (14). Finally the PBD-5,11-diones (15) with diversity in the C-ring have been obtained by cyclative cleavage of amino resins (14) employing lithiated 5-phenyl-2-oxazolidinone.
Further, the mesyl group of N-(2-azidobenzoyl)-4-methylsulfonyl oxypyrrolidine-2-carboxylic acid resins 12 is treated with NaN3 to give the bis-azido resins (16). These compounds are then reacted with a ten fold excess of triphenylphosphine in dry toluene at room temperature to produce the iminophosphoranes (16a) and these upon condensation with benzaldehyde 7 provide the corresponding imine resins (17). These imine resins are reduced with NaCNBH3 in 1% AcOH-DMA to give the amino resins (18), which upon cyclative cleavage with lithiated 5-phenyl-2-oxazolidinone afford the desired C-ring 2-amino substituted PBD-5,11-diones (19). 
The building blocks for the library synthesis (prolines, 2-azidobenzoic acids, aldehydes, carbonyl and sulfonyl chlorides) have been selected and used for the generation of 210 compound library with satisfactory yields of the final products 10, 15 and 19, comprising of 3 sub-libraries (126 + 81 + 3). 

These compounds have been screened for in vitro activity against Mycobacterium tuberculosis H37Rv at 50 g/mL concentration by using agar diffusion assay procedure. From the generated library of 210 compounds, 142 compounds have been screened and amongst these 25 compounds have shown to completely inhibit the growth of Mycobacterium tuberculosis (H37Rv ATCC 27294) at 50 g/mL concentrations (Figure 1).



A versatile approach for the solid-phase synthesis of PBD-5,11-diones has been developed. The diversity at N(10)-position can be created in a facile manner by employing this methodology. Moreover, the N-alkylation and esterification at C(2)-position has been achieved by employing this synthetic sequence. The reaction conditions used in this protocol are mild and compounds are obtained in good yields. This method can be potentially used for the generation of large number of pyrrolobenzodiazepine-based compounds using automated synthesizer. (Journal of Combinatorial Chemistry, 2006, in press)

Chapter III
Development of Solid Phase Synthetic Strategies for Pyrrolobenzodiazepine Antitumour Antibiotics

The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a group of potent, naturally occurring, antitumour antibiotics produced by various Streptomyces species. These compounds bind selectively in the minor groove of DNA while a covalent aminal bond between the electrophilic C11-position of the PBD and the nucleophilic N2-amino group of a guanine base, possibly result in the biological activity. A number of naturally occurring and synthetic compounds based on this PBD ring system, such as anthramycin, chicamycin, abbeymycin, DC-81 and its dimers have shown varying degrees of DNA binding affinity and anticancer activity. Moreover, pyrrolo[2,1-c][1,4]benzodiazepine-5,11-diones (PBD-5,11-diones) are known as non-covalent interactive minor groove binders. These are also intermediates for the synthesis of structurally modified PBD-imines via oxidation of secondary amines or by the reduction of N-protected dilactams. Further, these are known to exhibit different type of biological properties such as antiphage activity, analgesic antagonist, anti-inflammatory, psychomotor depressant activity and herbicidal properties. There are many methods known for the solution phase synthesis of PBD imines. However, there are only few reports on the solid phase synthesis of these PBD antitumour antibiotics.
This chapter has been divided into three sections. Section A consists of the reduction of aromatic nitro/azido functionality on solid-support employing Al/NiCl2.6H2O and Al/NH4Cl and these reagents have been applied for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines on solid-support. Section B deals with a new traceless approach for the solid-phase synthesis of pyrrolo[2,1-c][1,4]benzodiazepines involving intramolecular aza-Wittig cyclization through reductive cleavage by employing DIBAL-H. Section C comprises of the solid phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines by using chloromethyl Wang resin attached to isatoic anhydride as the starting material and synthetic route involving cyclocondensation followed by reductive cleavage.

Section A:
Reduction of Aromatic Nitro/Azido Functionality on Solid Support Employing Al/NiCl2.6H2O and Al/NH4Cl: Synthesis of Pyrrolobenzodiazepines

The preparation of small molecule libraries on solid phase is emerging as an expedient method and is being utilized towards generating compounds for screening against biological systems, and enhances the drug discovery effort. Since many combinatorial libraries are generated on solid support, adapting standard synthetic transformations to the solid phase is an essential part of increasing the range of compounds, which are accessible by this technique. 
The reduction of aromatic nitro/azido functionalities to corresponding amines is an important transformation in synthetic organic chemistry, used to construct a variety of biologically active molecules, especially in heterocyclic and medicinal chemistry. In solution-phase chemistry, the reduction of aromatic nitro/azido functionalities is readily accomplished with a wide variety of reagents. Many of these methods, however, require heavy metal catalysts, acid conditions, high temperatures or pressure, which renders most of them not suitable for application to solid phase organic chemistry. However, relatively few reagents are known for this synthetically and industrially important reaction on a solid support.
In recent years, aluminium based reagents have been found wide applications in synthetic chemistry because of their ready availability, easy handling and low costs. In the present work in search of a solid-phase compatible method a process by employing Al/NiCl2·6H2O and Al/NH4Cl reagent systems has been developed for the reduction of aromatic nitro/azido functionality (1) to the amino functionality (2) (Scheme 1).



Solid Phase Synthesis of Pyrrolobenzodiazepines Employing Al/NiCl2·6H2O and Al/NH4Cl

In continuation of these efforts towards the development of solid-phase synthetic methodologies for PBD ring systems, a neutral, mild and efficient method has been employed using Al/NiCl2·6H2O or Al/NH4Cl reagent system. In this investigation the solid phase procedure has been applied for the synthesis of biologically important compounds, particularly C2-hydroxy imine-containing PBD ring systems and their 5,11-diones. As reported in the literature, that C-ring hydroxy substitution plays an important role in executing the biological activities as seen in case of naturally occurring PBDs such as chicamycin A and B, neothramycin A and B, and abbemycin. 
Fmoc-protected 4-hydroxy proline methylester (5) has been obtained from commercially available trans-4-hydroxy proline (3) by employing thionyl chloride in methanol to give the trans-4-hydroxy proline methylester hydrochloride (4). This upon protection with Fmoc-Cl using triethylamine affords the Fmoc protected 4-hydroxy proline methylester (5) (Scheme 2).



The Wang resin (6) is activated as trichloroacetimidate (7) by Hanessian protocol and linked to the hydroxyl group of the N-Fmoc-protected trans-4-hydroxy proline methyl ester (5) to obtain the resin-bound N-Fmoc-protected trans-4-hydroxy proline methyl ester (8). The product, after cleavage of the Fmoc group using 20% piperidine/DMF, is coupled with 2-azidobenzoic acid (10) in the presence of DCC and DMAP to provide the amide resin 11. The reduction of ester group of 11 by DIBAL-H followed by reductive cyclization using Al/NiCl2·6H2O or Al/NH4Cl and cleavage affords the 2-hydroxy-7,8-substituted PBD imine (14). Furthermore, reductive cyclization of 11 using Al/NiCl2·6H2O or Al/NH4Cl affords the PBD-5,11-dione (15), which upon cleavage from the resin yields 2-hydroxy-7,8-substituted PBD-5,11-dione (16) (Scheme 3).
An efficient and cost effective solid phase synthesis of substituted arylamines from their corresponding nitro and azido substrates has been demonstrated. This procedure has been further extended towards the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines and their dilactams in good yields. This method is expected to generate combinatorial libraries for pyrrolo[2,1-c][1,4]benzodiazepines based compounds particularly those having a 2-hydroxy substituent on the C-ring (Tetrahedron Letters, 2003, 44, 4741).

Section B:
Solid-Phase Synthesis of Pyrrolobenzodiazepines Involving Reductive Cleavage

One of the challenges of the solid-phase combinatorial synthesis of heterocyclic compounds is developing chemical routes that provide access to the target compounds without leaving any trace of the linker used for tethering the starting building blocks to the solid support. The imine containing biologically significant pyrrolobenzodiazepine ring system is a reactive moiety and requires extremely mild conditions for the cleavage from the resin during its solid-phase synthesis. In the present investigation a new traceless approach for the solid-phase synthesis of pyrrolo[2,1-c][1,4]benzodiazepines based on reductive cleavage followed by cyclization employing DIBAL-H has been developed. 
Treatment of Wang resin (6) with thionylchloride gives the chloro Wang resin (17). Chloro Wang resin (17) on treating with potassium thioacetate in DMF has provided the thioester resin 18. The reduction of 18 using LiBH4 in THF at room temperature gives the thiol Wang resin 19 (Scheme 4).



The precursor Boc protected proline acid chloride (22) has been prepared by treating L-prolines (20) with Boc anhydride in presence of 2N NaOH solution followed by polystyrene triphenylphosphine (PS-TPP) in CCl4 (Scheme 5). This method is advantageous as it avoids the use of acid liberating reagents like SOCl2, (COCl)2 that leads to BOC-deprotection.



The resin 19 is attached to the Boc protected proline acid chloride (22) using triethylamine in dichloromethane to afford Boc protected proline thioester resin 23. The intermediate (24), after the deprotection of the Boc group using TFA, is coupled to the corresponding 2-azidobenzoic acid (10) in the presence of TBTU and DIPEA to provide the required resins (25). Treatment of 25 with excess of TPP in dry toluene at room temperature produced the corresponding resins of iminophosphoranes (26). Finally, the resins 26 have been treated with DIBAL-H in dry dichloromethane at -78 oC for 12 h to afford the desired PBD imines (27) (Scheme 6) in good yields (57–65%). Further, amino resins (28) have been obtained from reduction of 25 with TPP and THF-water. Finally, the dilactams (29) were obtained from cleavage of resin 28 with K2CO3 and MeOH. 


A new traceless solid-phase strategy for imine-containing pyrrolo[2,1-c][1,4]benzodiazepine ring systems has been demonstrated. This is an interesting process involving intramolecular aza-Wittig cyclization through reductive cleavage by employing DIBAL-H. These reaction conditions are readily amenable for generating a PBD combinatorial library with diversity in A and C rings (Tetrahedron Letters, 2004, 45, 7667).

Section C:
Solid-Phase Synthesis of Pyrrolobenzodiazepines Involving Cyclo Condensation

The traceless solid-phase synthesis, in which the group used for the attachment to solid supports is not left with the final target molecule, holds great importance because it is established fact that the functional group has a dramatic effect on the biological efficacy of the molecule. In some cases, the functional group left on the target molecule may not be desired for bioactivity and may limit the final structural optimization.
The interesting biological activity exhibited by imine containing PBDs and their dilactam analogues prompted for the development of a new expeditious solid-phase synthetic methodology for the preparation of these compounds. In the present investigation, imine containing PBDs have been prepared on solid-phase by altogether a new and practical approach that involves the use of polymer-bound isatoic anhydrides as starting materials. This in turn is coupled with corresponding prolines in DMF at 100-110 ºC to afford the polymer-bound PBD-5,11-diones. It is observed that by use of ultrasound in this step it not only reduces the time of the reaction but also maintains temperature around 50 oC instead of the usual high temperature (>100 oC). These resin bound PBD-5,11-diones upon mild reduction with lithium borohydride or sodium borohydride provide the polymer-bound carbinolamines and finally cleavage of the resin affords the desired PBD imines. This is one of shortest route for the solid-phase synthesis of imine containing PBDs that involves four steps with good overall yields (60-66%). 
The chloromethyl Wang resin (17) and various substituted isatoic anhydrides (30) have been prepared by known literature methods. The chloro Wang resin was attached to the isatoic anhydrides to produce the resin bound isatoic anhydrides (31). These isatoic anhydrides (31) attached to chloromethyl Wang resin are treated with L-proline or trans-4-hydroxyproline to afford the corresponding polymer-bound PBD-5,11-diones (32). These are reduced with lithium borohydride or sodium borohydride to give carbinolamine PBD resins (33). Finally, the resin is cleaved by TFA/H2O to provide the crude products (34) (Scheme 7). Furthermore, these polymer-bound PBD-5,11-diones (32) upon cleavage by TFA/H2O gives PBD dilactams (35) and are further purified by column chromatography.



An efficient, cost-effective and practical solid-phase synthesis of pyrrolo[2,1-c][1,4]benzodiazepines and their dilactams have been demonstrated by employing substituted isatoic anhydrides. This methodology is highly suitable for the generation of a combinatorial library, not only of PBD imines but also of PBD-5,11-diones with diversity in both the A and C rings (Synlett, 2004, 1841)

Chapter IV
Polymer Assisted Solution Phase Strategy for the Synthesis of Pyrrolobenzodiazepines Anticancer Agents

In the last few years, the use of solution-phase methods has received a considerable amount of attention for the parallel synthesis of low molecular weight compound libraries. Moreover, in the field of solution phase library generation, the use of polymer-supported reagents is emerging as a leading strategy that not only gives the advantage of product isolation and purification of solid phase chemistry but also provides the benefits of the traditional solution-phase reactions. 
The imine or carbinolamine-containing pyrrolo[2,1-c][1,4]benzodiazepines are a family of low molecular weight natural products originally isolated from Streptomyces species, that are known to exhibit antitumour activity. These antibiotics bind selectively in the minor groove of DNA while a covalent aminal bond is formed between the electrophilic C11-position of the PBD and the nucleophilic N2-amino group of a guanine base, resulting in biological activity. The S-configuration at the chiral C11a-position provides the PBD structure with the necessary right handed twist to fit snugly within the minor groove. In conjunction with these efforts and to the best of my knowledge, for the first time polymer-supported reagents has been used for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines. Further, dilactams are known to exhibit different type of biological properties such as antiphage activity, analgesic antagonist, anti-inflammatory, psychomotor depressant activity and herbicidal properties.
Starting materials prolinol (3) and proline methyl ester (5) have been prepared from the commercially available L-proline by employing polymer supported reagents. L-Prolinol (3) has been obtained from L-proline (1) by reduction with borohydride exchange resin (2) (BER). Proline esterification has been carried out on L-proline employing amberlyst 15 (4) in MeOH. By this method water-soluble prolinol and proline methyl ester isolation becomes easier as this avoids water work-up unlike the conventional methods (Scheme 1).



The synthetic route consists of the coupling of L-prolinol (3) with the corresponding 2-azidobenzoic acids (6). Interestingly, in the coupling reaction of prolinol (3) to the azido benzoic acid (6) by using polymer-supported cyclohexylcarbodiimide (7), the excess of acid and urea by-products can be simply filtered from the azido alcohols 8. Upon oxidation by modified Swern procedure using polymer-supported sulfoxide (9a) (PSS), compounds 8 afford the azido aldehydes 10, which, upon intramolecular reductive cyclization with polymer-supported TPP (11), afford the desired imines 12 containing the pyrrolobenzodiazepine ring system. The oxidation of 8 have also been carried out by employing polymer-supported perruthenate (9b) (PSP) as an alternative reagent. The use of PSS (9a) and PSP (9b) makes this method devoid of the unpleasant smell of dimethylsulfide and further the formation of polymer-linked phosphine oxide can be easily filtered out from the PBD imines. In the case of 12, debenzylation by employing Pd/C provides the naturally occurring DC-81 (13). The PBD dilactams (15) have also been obtained by polymer-supported reagents employing L-proline methyl ester (5) instead of L-prolinol to yield PBD dilactams 15 (Scheme 2).



An efficient procedure has developed for the clean preparation of imine-containing PBDs starting from L-proline and azido benzoic acids using polymer-supported reagents. It is noteworthy in the entire process, the work-up has been simplified to filtration and evaporation for all the steps. Application of this protocol has generated an array of imine-containing PBDs and their dilactam derivatives, and further, in this methodology all the reagents could be reused thus addressing the problems of environmental and economical sustainability (‘green’ chemistry) (Synlett, 2004, 2523)
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